Finally, the effect of the recent development of KIT/PDGFRA inhibitors is ripretinib (formerly DCC-2618), whose effectiveness in inhibition of a wide range of KIT mutants in patients with drug-resistant GISTs has been confirmed in preclinical cancer models and preliminary clinical data [70]. This evidence concerns the gene KIT and cancer.